A healthy-volunteer study found a modest midazolam exposure change at one tested inhibitor regimen. It did not establish an impairment or dose-adjustment rule for every patient.
The interaction experiment
The phase-one program included an open-label component using oral midazolam as a CYP3A index substrate. At the higher BAY 2433334 regimen on day ten, the midazolam exposure ratio was approximately 1.17. The metabolite ratio was close to one.
The authors interpreted the overall findings as lacking clinically relevant CYP3A induction or inhibition under the studied conditions.
Exposure and clinical effect differ
A concentration–time area measures systemic exposure, not anxiety relief, memory, airway function, or driving performance. A modest average change can also coexist with variation among individuals.
The participants were healthy men in a controlled early-phase study. Illness, additional medicines, and other regimens were not all represented. The paper supports a specific interaction assessment, but cannot justify treating every benzodiazepine as equivalent or calculating an individual impairment level from the reported exposure ratio.
Source paper
Original analysis of the supplied journal article, identified as PMC9311154.
Leave a Reply